Search
Calcium levulinate
go.drugbank.com/drugs/DB13800ApprovedThe relatively new calcium levulinate is produced from a direct reaction between L- or levulinic acid levulose and calcium hydroxide [L2765]. … The resultant calcium levulinate formulation, when used as a calcium supplement, possesses a high calcium content that is observed to be 14.8% higher than the content typically found in calcium lactate
Vigabatrin
go.drugbank.com/drugs/DB01080ApprovedInvestigational[A202124] Its use is now generally reserved for patients who have failed alternative therapies, and its US approval by the FDA in 2009 mandated the creation of a drug registry to monitor patients for visual
1,2-dichlorobenzene
go.drugbank.com/drugs/DB13963ApprovedWithdrawnan insecticide and as an agent to remove carbon-based contamination from metal. … This derivative of benzene differs from the parent compound by the presence of two adjacent chlorine atoms. 1,2-dichlorobenzene is used as a precursor for agrochemicals, as a solvent for fullerenes, as
Synonyms: o-Dichlorbenzol, o-dichlorbenzeneGadodiamide
go.drugbank.com/drugs/DB00225ApprovedInvestigational[A263096] Approved by the FDA in 1993, gadodiamide is the first non-ionic GBCA to be used. … [A263101] However, since linear, non-ionic GBCA is less stable than macrocyclic or ionic GBCA, gadodiamide can potentially lead to more gadolinium retention in the brain and thus more likely to cause side
Nivolumab
go.drugbank.com/drugs/DB09035ApprovedInvestigational[A35203] It was developed by Bristol Myers Squibb.[L12129] Nivolumab was granted FDA approval on 22 December 2014.
Dihydroergotamine
go.drugbank.com/drugs/DB00320ApprovedInvestigational[L38469] Its use has largely been supplanted by triptans in current therapy due to the class's greater selectivity and more favourable side effect profile. … Recent improvements have been made in the design of intranasal delivery devices allowing for greater delivery of dihydroergotamine solution to the vasculature-rich upper nasal cavity.
Synonyms: (2R,4R,7R)-N-[(1S,2S,4R,7S)-7-benzyl-2-hydroxy-4-methyl-5,8-dioxo-3-oxa-6,9-diazatricyclo[7.3.0.02,6]dodecan-4-yl]-6-methyl-6,11-diazatetracyclo[7.6.1.02,7.012,16]hexadeca-1(16),9,12,14-tetraene-4-carboxamideCategories: Serotonergic Drugs Shown to Increase Risk of Serotonin SyndromePhenylbutyric acid
go.drugbank.com/drugs/DB06819ApprovedInvestigational[A249035] It is used to treat genetic metabolic syndromes, neuropathies, and urea cycle disorders.[L386,L42105] … Phenylbutyric acid is a fatty acid and a derivative of [butyric acid] naturally produced by colonic bacteria fermentation.
Synonyms: 4-Phenyl-n-butyric acid, γ-Phenyl-n-butyric acidLumefantrine
go.drugbank.com/drugs/DB06708ApprovedInvestigational</i> and may be used to treat infections caused by <i>P. falciparum</i> and unidentified <i>Plasmodium</i> species, including infections acquired in chloroquine-resistant areas. … Lumefantrine is an antimalarial agent used to treat acute uncomplicated malaria. It is administered in combination with artemether for improved efficacy.
Synonyms: (±)-2,7-Dichloro-9-((Z)-p-chlorobenzylidene)-α-((dibutylamino)methyl)fluorene-4-methanol, 2-Dibutylamino-1-{2,7-dichloro-9-[1-(4-chloro-phenyl)-meth-(Z)-ylidene]-9H-fluoren-4-yl}-ethanolEthionamide
go.drugbank.com/drugs/DB00609ApprovedInvestigationalWithdrawn(From Smith and Reynard, Textbook of Pharmacology, 1992, p868)
Enasidenib
go.drugbank.com/drugs/DB13874ApprovedInvestigationalFirst developed by Agios Pharmaceuticals and licensed to Celgene, enasidenib was approved by U.S. Food and Drug Administration on August 1, 2017. … This small molecule acts as an allosteric inhibitor of mutant IDH2 enzyme to prevent cell growth, and it also has shown to block several other enzymes that play a role in abnormal cell differentiation.